A First – Smartphone Diagnostic Device Replicates Quality of Lab Blood Test
|
By LabMedica International staff writers Posted on 09 Feb 2015 |

Image: Newly developed diagnostic smartphone accessory device successfully performed point-of-care HIV and syphilis tests in Rwanda from finger-prick whole blood in 15 minutes, operated by healthcare workers easily trained via a software app (Photo courtesy of Samiksha Nayak for Columbia Engineering).
Researchers have developed a hand-held smartphone accessory that can perform a low-cost, point-of-care (POC), lab-quality test that simultaneously detects 3 infectious disease markers from a single finger-prick blood sample in only 15 minutes. The device can also be further developed to test for additional biomarkers.
In a multi-institutional collaboration, the team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering (New York, NY, USA), developed and field-tested the miniature device that, for the first time, replicates all mechanical, optical, and electronic functions of a lab-based blood test. Specifically, it performs an enzyme-linked immunosorbent assay (ELISA), without requiring stored energy as all necessary power is drawn from the smartphone. It also performs a triplexed immunoassay not currently available in a single test format: HIV antibody, treponemal-specific antibody for syphilis, and non-treponemal antibody for active syphilis infection.
Prof. Sia’s innovative accessory (or dongle) was recently piloted by healthcare workers in Rwanda, who trained via a software app then tested 96 patients from prevention-of-mother-to-child-transmission clinics or voluntary counseling and testing centers.
“Our work shows that a full laboratory-quality immunoassay can be run on a smartphone accessory,” said Prof. Sia, “Coupling microfluidics with recent advances in consumer electronics can make certain lab-based diagnostics accessible to almost any population with access to smartphones. This kind of capability can transform how health care services are delivered around the world.”
Prof. Sia’s team built upon their previous work in miniaturizing diagnostics hardware for rapid POC diagnosis of HIV, syphilis, and other sexually transmitted diseases. “We know that early diagnosis and treatment in pregnant mothers can greatly reduce adverse consequences to both mothers and their babies,” Sia notes. The team developed the dongle to be small and light enough to fit into one hand, and to run assays on disposable plastic cassettes with pre-loaded reagents, where disease-specific zones provide an objective read-out, much like an ELISA assay.
Prof. Sia estimates the dongle will have a manufacturing cost of USD 34, much lower than the USD 18,450 that typical ELISA equipment runs.
The team made two main innovations to achieve low power consumption, a must in places without dependable electricity. They eliminated the power-consuming electrical pump by using a “one-push vacuum,” where a user mechanically activates a negative-pressure chamber to move a sequence of reagents pre-stored on a cassette. The process is durable, requires little user training, and needs no maintenance or additional manufacturing. The team was able to implement a second innovation to remove the need for a battery by using the audio jack for transmitting power as well as for data transmission. And, because audio jacks are standardized among smartphones, the dongle can be attached to any compatible device (including iPhones and Android phones) in a simple plug-and-play manner.
During the field testing in Rwanda, healthcare workers were given 30 minutes of training, which included a user-friendly interface, step-by-step pictorial directions, built-in timers to alert to next steps, and records of test results for later review.
The work, by Laksanasopin T, Guo TW, et al., was published February 4, 2015, in the journal Science Translational Medicine.
Related Links:
Columbia Engineering
In a multi-institutional collaboration, the team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering (New York, NY, USA), developed and field-tested the miniature device that, for the first time, replicates all mechanical, optical, and electronic functions of a lab-based blood test. Specifically, it performs an enzyme-linked immunosorbent assay (ELISA), without requiring stored energy as all necessary power is drawn from the smartphone. It also performs a triplexed immunoassay not currently available in a single test format: HIV antibody, treponemal-specific antibody for syphilis, and non-treponemal antibody for active syphilis infection.
Prof. Sia’s innovative accessory (or dongle) was recently piloted by healthcare workers in Rwanda, who trained via a software app then tested 96 patients from prevention-of-mother-to-child-transmission clinics or voluntary counseling and testing centers.
“Our work shows that a full laboratory-quality immunoassay can be run on a smartphone accessory,” said Prof. Sia, “Coupling microfluidics with recent advances in consumer electronics can make certain lab-based diagnostics accessible to almost any population with access to smartphones. This kind of capability can transform how health care services are delivered around the world.”
Prof. Sia’s team built upon their previous work in miniaturizing diagnostics hardware for rapid POC diagnosis of HIV, syphilis, and other sexually transmitted diseases. “We know that early diagnosis and treatment in pregnant mothers can greatly reduce adverse consequences to both mothers and their babies,” Sia notes. The team developed the dongle to be small and light enough to fit into one hand, and to run assays on disposable plastic cassettes with pre-loaded reagents, where disease-specific zones provide an objective read-out, much like an ELISA assay.
Prof. Sia estimates the dongle will have a manufacturing cost of USD 34, much lower than the USD 18,450 that typical ELISA equipment runs.
The team made two main innovations to achieve low power consumption, a must in places without dependable electricity. They eliminated the power-consuming electrical pump by using a “one-push vacuum,” where a user mechanically activates a negative-pressure chamber to move a sequence of reagents pre-stored on a cassette. The process is durable, requires little user training, and needs no maintenance or additional manufacturing. The team was able to implement a second innovation to remove the need for a battery by using the audio jack for transmitting power as well as for data transmission. And, because audio jacks are standardized among smartphones, the dongle can be attached to any compatible device (including iPhones and Android phones) in a simple plug-and-play manner.
During the field testing in Rwanda, healthcare workers were given 30 minutes of training, which included a user-friendly interface, step-by-step pictorial directions, built-in timers to alert to next steps, and records of test results for later review.
The work, by Laksanasopin T, Guo TW, et al., was published February 4, 2015, in the journal Science Translational Medicine.
Related Links:
Columbia Engineering
Latest Immunology News
- Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
- Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
- Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
- Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
- Airway Immune Signature May Predict Tuberculosis Progression Risk
- New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
- Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes
- Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
- Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis and Management Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read moreMolecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read morePathology
view channel
FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
Prostate cancer is the most common cancer among U.S. men, with more than 300,000 new cases and over 36,000 deaths each year. As targeted therapies emerge for biomarker-defined subgroups, laboratories need... Read more
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more








